Status:
COMPLETED
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
Lead Sponsor:
Ligand Pharmaceuticals
Conditions:
Bone Loss
Eligibility:
FEMALE
50+ years
Phase:
PHASE2
Brief Summary
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
Eligibility Criteria
Inclusion
- Postmenopausal women over 50 years who have low bone mineral density.
Exclusion
- Women who are under 50 years of age, are premenopausal, or who currently have osteoporosis are excluded.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00674453
Start Date
September 1 2004
End Date
September 1 2007
Last Update
August 10 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Sheffield, United Kingdom, S5 7AU